These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38057215)

  • 1. Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
    Topkan E; Somay E; Selek U; Pehlivan B
    Eur J Cancer; 2024 Mar; 200():113459. PubMed ID: 38057215
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
    Guo SS; Yang JH; Sun XS; Liu LZ; Yang ZC; Liu LT; Liu SL; Li XY; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Liang YJ; Jia GD; Zhao C; Chen QY; Tang LQ; Mai HQ
    Eur J Cancer; 2023 Nov; 194():113336. PubMed ID: 37801967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
    Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
    Xue F; He X
    Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus.
    Vasudevan HN; Yom SS
    Hematol Oncol Clin North Am; 2021 Oct; 35(5):963-971. PubMed ID: 34187713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification:
    Ng WT; Chua MLK; Lee AWM
    J Clin Oncol; 2022 Apr; 40(11):1135-1138. PubMed ID: 35213233
    [No Abstract]   [Full Text] [Related]  

  • 7. Epstein-Barr virus DNA detection by targeted sequencing in post-treatment plasma samples and prognosis of locally advanced nasopharyngeal cancer: implications for clinical research.
    Economopoulou P; Lianidou E; Psyrri A
    Ann Oncol; 2022 Aug; 33(8):747-749. PubMed ID: 35598800
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to "Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma".
    Akhtar A; Akhtar R; Nasir BM
    Oral Oncol; 2024 Feb; 149():106674. PubMed ID: 38154446
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter to the editor regarding "EBV-LMP1 suppresses the DNA damage response through DNA-PK/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma".
    Lin J
    Cancer Lett; 2021 Nov; 520():281. PubMed ID: 34384809
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
    Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
    Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus: the path from association to causality for a ubiquitous human pathogen.
    Sugden B
    PLoS Biol; 2014 Sep; 12(9):e1001939. PubMed ID: 25180782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma.
    Lee VH; Kwong DL; Leung TW; Choi CW; Lam KO; Sze CK; Ho P; Chan WL; Wong LS; Leung D
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):42-9. PubMed ID: 26482452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions.
    Lam WKJ; King AD; Miller JA; Liu Z; Yu KJ; Chua MLK; Ma BBY; Chen MY; Pinsky BA; Lou PJ; Woo JKS; Hsu WL; Simon J; Doolan DL; Waterboer T; Hui EP; Li H; Tsang RK; Wong KCW; Goh JP; Vlantis AC; Ai QY; Wong LM; Abdullah V; Lin JC; Chen CJ; Pfeiffer RM; Le QT; Lee AWM; Ji M; Cao S; Ma J; Chan ATC; Chan KCA; Hildesheim A
    J Natl Cancer Inst; 2023 Apr; 115(4):355-364. PubMed ID: 36723440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric EBV+ Nasopharyngeal Carcinoma With Complete ICA Occlusion.
    Villela VA; Morales-León JF; Cavigli A; Palacios E
    Ear Nose Throat J; 2022 May; 101(4):228-230. PubMed ID: 32862722
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and survival analysis of nasopharyngeal carcinoma with consistently negative Epstein-Barr virus DNA.
    Wei ZG; Hu XL; He Y; Guan H; Wang JJ; He L; Mu XL; Liu ZR; Li RD; Peng XC
    Head Neck; 2021 May; 43(5):1465-1475. PubMed ID: 33421240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.